News | Patient Engagement | October 19, 2017

Smartphone Apps Help Patients and Providers Manage Atrial Fibrillation

My AF and AF Manager apps share patient data to maximize face-to-face time

Smartphone Apps Help Patients and Providers Manage Atrial Fibrillation
My AF and AF Manager apps are freely available for Android and iOS devices through the Google Play and Apple stores

October 19, 2017 — Novel smartphone and tablet applications for atrial fibrillation patients and healthcare professionals have been launched by heart experts. The objectives and design of the apps are outlined in a paper published online in EP Europace,1 with a summary published in the European Heart Journal.2

Atrial fibrillation is the most common heart rhythm disorder and significantly increases the risk of stroke and death. One in four middle-aged adults in Europe and the U.S. will develop atrial fibrillation, and the incidence and prevalence are rising.

“Around two-thirds of people in Europe and the U.S. have a mobile device and use it as their main way of accessing online information,” said lead author  Dipak Kotecha, MbChB, Ph.D., a clinician scientist in cardiovascular medicine at the Institute of Cardiovascular Sciences, University of Birmingham, U.K. “This presents a big opportunity to improve self management and shared decision making in atrial fibrillation.”

The My AF app and AF Manager app were designed by the European Society of Cardiology (ESC) Guidelines Task Force on Atrial Fibrillation and the CATCH ME consortium, of which the ESC is a partner. The apps were developed over the last two years in tandem with the writing of the 2016 ESC Guidelines on atrial fibrillation.3

Both apps are freely available for Android and iOS devices through the Google Play and Apple stores. (see figure 1)

My AF is for patients with atrial fibrillation. It provides information about the condition, the risk of stroke, atrial fibrillation treatments and tips on improving lifestyle. Patients can record symptoms and quality of life in a diary which can be shared with a nominated health professional before each consultation to maximize face-to-face time.

Developed in collaboration with patients and patient support groups, My AF provides high-quality information in a simple format which is suitable for adults of all ages. Work is underway to translate the app into several languages.

Kotecha said, “The app aims to encourage active patient involvement in the management of their condition. There is evidence that patient education can improve self-care, adherence to therapy and long-term outcomes.”

AF Manager is for doctors, nurses and other healthcare professionals. It is the first app of its kind to be submitted for CE certification and is in the final stages of approval. AF Manager imports information shared by the patient and allows the healthcare professional to amend details and enter other medical information, such as electrocardiogram or echocardiography data. The Treatment Manager tool within the app then suggests individualized treatment options based on ESC guidelines.4 After a consultation, the notes, treatment decisions and medication dosages can be entered and then shared with the patient.

“Many studies have shown that when clinicians follow guideline recommendations, patients have better outcomes,” said Kotecha. “All of the decision aids in AF Manager are based on ESC guidelines, so we hope this will encourage guideline implementation. Patients will have the option to anonymously donate their data which will enable us to assess the guideline adherence rate.”

The apps are linked to allow transfer of data between patients and healthcare professionals via a secure server at the University of Birmingham, U.K. Patients control who can view and edit their data. When data sharing is enabled, updates are synced on both apps. All shared information is encrypted and password protected.

Kotecha said, “We know that effective management of atrial fibrillation is suited to shared decision-making and we have created the apps in the hope of facilitating this process. Sharing information should save clinicians time and enable them to devote consultations to choosing the best treatments.”

He concluded, “The dynamic nature of this technology will allow us to modify and update the features and content to reflect feedback from users, as well as future versions of the ESC atrial fibrillation guidelines.”

For more information: www.escardio.org

 

Related Cardiac App and Wearable Related Articles

How Smartphones and Apps May Change the Face of Healthcare

The Uberization of Healthcare

Wearable Sensor Technology Trending Upward Rapidly in Healthcare

 

References

1. Kotecha D, et al. European Society of Cardiology (ESC) smartphone and tablet applications for patients with atrial fibrillation and their healthcare providers. EP Europace. 2017. DOI: 10.1093/europace/eux299

2. Kotecha D, Kirchhof P. ESC Apps for Atrial Fibrillation. Eur Heart J. 2017;38:2643–2645.

3. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893–2962. doi: 10.1093/eurheartj/ehw210

4. The full capabilities of the Treatment Manager tool will be available once the app is CE certified.

Related Content

Boston Scientific's Apama multi-electrode ablation balloon to treat atrial fibrillation.

Boston Scientific's Apama multi-electrode ablation balloon to treat atrial fibrillation. The technology allows different energies to be used for each electrode to prevent damage to the esophagus or other underlying critical structures. 

Feature | Atrial Fibrillation | January 15, 2018 | Dave Fornell
The development of atrial fibrillation (AFib or AF) ablation technologies over the past 20 years has been a constant
Heart Rhythm Society Partners With WebMD Education to Increase Atrial Fibrillation Awareness
News | Atrial Fibrillation | January 02, 2018
The Heart Rhythm Society (HRS), in partnership with WebMD Education, announced in December the launch of a free, online...
The Boston Scientific Rhythmia Mapping System produces higher-density voltage maps without increasing overall procedure time.

The Boston Scientific Rhythmia Mapping System produces higher-density voltage maps without increasing overall procedure time. It was the first of a new generation of high-density mapping systems to be introduced.

Feature | Atrial Fibrillation | December 18, 2017 | Kenneth Stein, M.D. FACC FHRS
When I began practicing as an electrophysiologist in 1994, the dream of successfully using cardiac catheter ablation
Acutus dipole density EP mapping for ablation procedures.

The FDA recently cleared high-speed Acutus Medical's AcQMap High Resolution image and mapping system and the AcQMap 3-D Imaging and Mapping Catheter.  detects and displays both standard voltage-based and higher resolution dipole density (charge-source) maps. The system combines ultrasound anatomy construction with an ability to map the electrical-conduction of each heartbeat to identify complex arrhythmias across the entire atrial chamber. Following each ablation treatment, the heart can be re-mapped in seconds to continually visualize any changes from the prior mapping.

 

 

Feature | Atrial Fibrillation | November 07, 2017
November 7, 2017 — Here is an aggregated list of articles detailing the latest clinical data and new device technolog
The Watchman LAA occluder PREVAIL Trial 5-year results were presented at the 2017 TCT meeting.
Feature | Atrial Fibrillation | November 02, 2017
November 2, 2017 – Five-year results from the PREVAIL Trial comparing left atrial appendage closure (LAAC) with the B
UNC School of Medicine Receives $1.7 Million for Atrial Fibrillation Program Streamlining Patient Care
News | Atrial Fibrillation | October 23, 2017
October 23, 2017 — University of North Carolina (UNC) School of Medicine cardiologist Anil Gehi, M.D., will use a $1.
EMANATE Trial Shows Apixaban Lowers stroke in AF Patients Undergoing Cardioversion.
News | Atrial Fibrillation | September 01, 2017
September 1, 2017 — Apixaban lowers the risk of stroke compared to warfarin in anticoagulation-naïve patients with at
CASTLE-AF Study shows Catheter Ablation of Atrial Fibrillation is First-Line Treatment for Heart Failure Patients. Biotronic Ilivia 7 ICD.

The CASTLE-AF Study shows catheter alation of AF can be used effectively to treat heart failure in patients with an implanted ICD.

News | Atrial Fibrillation | September 01, 2017
September 1, 2017 — Final results from the CASTLE-AF study show a 38 percent reduction in the composite of all-cause
Overlay Init